Hengrui Medicine (01276.HK): SHR-3045 Injection Approved for Clinical Trials.

The Zhitong Finance News App reported that Jiangsu Hengrui Medicine Co., Ltd. (01276.HK) issued an announcement stating that its subsidiaries, Guangdong Hengrui Medicine Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd., have received the Drug Clinical Trial Approval Notice from the National Medical Products Administration (referred to as the "NMPA" below) regarding the SHR-3045 injection. Clinical trials will be conducted in the near future.